Documents
-
- Download
- Part VI: Chapter 12
- open access
-
- Download
- Part VI: Chapter 13: Summary in Dutch
- open access
-
- Download
- Part III: Chapter 5
- open access
- Full text at publishers site
-
- Download
- Part III: Chapter 8
- open access
-
- Download
- Part IV: Chapter 10
- open access
-
- Download
- Part III: Chapter 7
- open access
-
- Download
- Propositions
- open access
-
- Download
- Part I: Chapter 1
- open access
-
- Download
- Part II: Chapter 3
- open access
- Full text at publishers site
-
- Download
- Title Pages_Contents
- open access
-
- Download
- Part I: Chapter 2
- open access
- Full text at publishers site
-
- Download
- Part V: Chapter 11
- open access
- Full text at publishers site
-
- Download
- Part II :Chapter 4
- open access
-
- Download
- Part III: Chapter 6
- open access
- Full text at publishers site
-
- Download
- Part IV: Chapter 9
- open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
Individualized dosing of serotherapy in allogeneic hematopoietic cell transplantation - a delicate balance
(HCT) to prevent graft-versus-host-disease (GvHD) and graft failure. Main toxicities include absent or slow immune reconstitution. This thesis aims to develop evidence based dosing regimens for both agents.
We found that current weight-based dosing of ATG and alemtuzumab lead to highly biased exposures across the different age groups in the pediatric population. Furthermore, ATG clearance was not found to increase with increasing body weight in patients over 50 kg (i.e. adolescents and adults). Timely CD4+ T-cell immune reconstitution after HCT is essential for reducing viral reactivations and relapse following HCT, and thereby improves survival chances. High exposure to ATG after infusion of the graft diminishes chances for CD4+ T-cell reconstitution....Show more
Anti-thymocyte globulin (ATG) and alemtuzumab are both used in hematopoietic cell transplantation
(HCT) to prevent graft-versus-host-disease (GvHD) and graft failure. Main toxicities include absent or slow immune reconstitution. This thesis aims to develop evidence based dosing regimens for both agents.
We found that current weight-based dosing of ATG and alemtuzumab lead to highly biased exposures across the different age groups in the pediatric population. Furthermore, ATG clearance was not found to increase with increasing body weight in patients over 50 kg (i.e. adolescents and adults). Timely CD4+ T-cell immune reconstitution after HCT is essential for reducing viral reactivations and relapse following HCT, and thereby improves survival chances. High exposure to ATG after infusion of the graft diminishes chances for CD4+ T-cell reconstitution. Therefore, exposure to ATG has a major impact on the clinical outcomes including survival following HCT in children and adults.
We conclude that individualizing dosing and timing of ATG potentially makes HCT a safer and more effective treatment option, and will lead to improved survival chances. Individualized dosing regimens for ATG in children have been designed based on the results in this thesis, and are currently being evaluated in prospective clinical trials for efficacy and safety.
Show less
- All authors
- Admiraal, R.
- Supervisor
- Knibbe, C.A.J.
- Co-supervisor
- Boelens, J.J.; Bredius, R.G.M.
- Committee
- Irth, H.; Danhof, M.; Falkenburg, J.H.F.; Gelder, T. van; Kesteren, C. van
- Qualification
- Doctor (dr.)
- Awarding Institution
- Leiden Academic Centre for Drug Research (LACDR), Science, Leiden University
- Date
- 2017-03-15